127 related articles for article (PubMed ID: 25613194)
1. The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.
Nikitina D; Llacuachaqui M; Sepkovic D; Bradlow HL; Narod SA; Kotsopoulos J
Fam Cancer; 2015 Jun; 14(2):281-6. PubMed ID: 25613194
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.
Kotsopoulos J; Zhang S; Akbari M; Salmena L; Llacuachaqui M; Zeligs M; Sun P; Narod SA
Br J Cancer; 2014 Sep; 111(7):1269-74. PubMed ID: 25025957
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.
Thomson CA; Chow HHS; Wertheim BC; Roe DJ; Stopeck A; Maskarinec G; Altbach M; Chalasani P; Huang C; Strom MB; Galons JP; Thompson PA
Breast Cancer Res Treat; 2017 Aug; 165(1):97-107. PubMed ID: 28560655
[TBL] [Abstract][Full Text] [Related]
4. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer.
Dalessandri KM; Firestone GL; Fitch MD; Bradlow HL; Bjeldanes LF
Nutr Cancer; 2004; 50(2):161-7. PubMed ID: 15623462
[TBL] [Abstract][Full Text] [Related]
5. Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups.
Jernström H; Klug TL; Sepkovic DW; Bradlow HL; Narod SA
Carcinogenesis; 2003 May; 24(5):991-1005. PubMed ID: 12771045
[TBL] [Abstract][Full Text] [Related]
6. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women.
Wu WH; Lu SC; Wang TF; Jou HJ; Wang TA
Eur J Clin Nutr; 2006 Mar; 60(3):386-92. PubMed ID: 16278686
[TBL] [Abstract][Full Text] [Related]
7. Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer.
Greenlee H; Chen Y; Kabat GC; Wang Q; Kibriya MG; Gurvich I; Sepkovic DW; Bradlow HL; Senie RT; Santella RM; Ahsan H
Breast Cancer Res Treat; 2007 Mar; 102(1):111-7. PubMed ID: 16850246
[TBL] [Abstract][Full Text] [Related]
8. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection.
Fowke JH; Qi D; Bradlow HL; Shu XO; Gao YT; Cheng JR; Jin F; Zheng W
Steroids; 2003 Jan; 68(1):65-72. PubMed ID: 12475724
[TBL] [Abstract][Full Text] [Related]
9. Effect of dietary soy isoflavone aglycones on the urinary 16alpha-to-2-hydroxyestrone ratio in C3H/HeJ mice.
Kishida T; Beppu M; Nashiki K; Izumi T; Ebihara K
Nutr Cancer; 2000; 38(2):209-14. PubMed ID: 11525599
[TBL] [Abstract][Full Text] [Related]
10. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study.
Wellejus A; Olsen A; Tjonneland A; Thomsen BL; Overvad K; Loft S
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2137-42. PubMed ID: 16172222
[TBL] [Abstract][Full Text] [Related]
11. Urinary estrogen metabolites and their ratio among Asian American women.
Falk RT; Fears TR; Xu X; Hoover RN; Pike MC; Wu AH; Nomura AM; Kolonel LN; West DW; Sepkovic DW; Bradlow HL; Ziegler RG
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):221-6. PubMed ID: 15668498
[TBL] [Abstract][Full Text] [Related]
12. 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial.
Yerushalmi R; Bargil S; Ber Y; Ozlavo R; Sivan T; Rapson Y; Pomerantz A; Tsoref D; Sharon E; Caspi O; Grubsrein A; Margel D
Carcinogenesis; 2020 Oct; 41(10):1395-1401. PubMed ID: 32458980
[TBL] [Abstract][Full Text] [Related]
13. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women?
Ursin G; Wilson M; Henderson BE; Kolonel LN; Monroe K; Lee HP; Seow A; Yu MC; Stanczyk FZ; Gentzschein E
Cancer Res; 2001 Apr; 61(8):3326-9. PubMed ID: 11309288
[TBL] [Abstract][Full Text] [Related]
14. The relation of urinary estrogen metabolites with mammographic densities in premenopausal women.
Maskarinec G; Heak S; Morimoto Y; Custer L; Franke AA
Cancer Epidemiol; 2012 Oct; 36(5):e310-6. PubMed ID: 22537763
[TBL] [Abstract][Full Text] [Related]
15. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
[TBL] [Abstract][Full Text] [Related]
16. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone in Caucasian women.
Chen Z; Zheng W; Dunning LM; Anderson KG; Parrish RS; Holtzman JL
Steroids; 1999 Dec; 64(12):856-9. PubMed ID: 10576221
[TBL] [Abstract][Full Text] [Related]
17. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis.
Barba M; Yang L; Schünemann HJ; Sperati F; Grioni S; Stranges S; Westerlind KC; Blandino G; Gallucci M; Lauria R; Malorni L; Muti P
J Exp Clin Cancer Res; 2009 Oct; 28(1):135. PubMed ID: 19814782
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
[TBL] [Abstract][Full Text] [Related]
19. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
20. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
